Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

References

• Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661–5. doi:10.1038/nature05541. PMID:17251932.
   PubMed Web of Science ®Google Scholar
• Wang B, Niu D, Lai L, Ren EC. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun. 2013;4:2359. doi:10.1038/ncomms3359. PMID:23965983.
   PubMed Web of Science ®Google Scholar
• Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene. 1999;18:7740–7. doi:10.1038/sj.onc.1203235. PMID:10618714.
   PubMed Web of Science ®Google Scholar
• Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, Mami-Chouaib F, Chouaib S. p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol. 2005;174:871–8. doi:10.4049/jimmunol.174.2.871. PMID:15634909.
   PubMed Web of Science ®Google Scholar
• Guo G, Yu M, Xiao W, Celis E, Cui Y. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Res. 2017;77:2292–305. doi:10.1158/0008-5472.CAN-16-2832. PMID:28280037.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82. doi:10.1038/nature14129. PMID:25631445.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Head & neck. 2011;33:131–4. doi:10.1002/hed.21364.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, ET AL. Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res : an official journal of the American Association for Cancer Research. 2009;15:7719–25. doi:10.1158/1078-0432.CCR-09-1044. PMID:19996201.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, ET AL. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2000;18:609–22. doi:10.1200/JCO.2000.18.3.609. PMID:10653876.
   PubMed Web of Science ®Google Scholar
• Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, ET AL. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res : an official journal of the American Association for Cancer Research. 2003;9:93–101. PMID:12538456.
   PubMed Web of Science ®Google Scholar
• Chen GX, Zhang S, He XH, Liu SY, Ma C, Zou XP. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther. 2014;7:1901–9. doi:10.2147/OTT.S50483. PMID:25364261.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH.. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–46. PMID:12489850.
   PubMed Web of Science ®Google Scholar
• Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF, Rait A, Chang EH. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med. 2001;7:723–34. PMID:11713371.
   PubMed Web of Science ®Google Scholar
• Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK.. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013;20:222–8. doi:10.1038/cgt.2013.9. PMID:23470564.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, Pirollo KF, Chang EH. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine. 2015;11:301–11. doi:10.1016/j.nano.2014.09.005. PMID:25240597.
   PubMed Web of Science ®Google Scholar
• Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo KF, Rait A, Chang EH. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther : the journal of the American Society of Gene Therapy. 2013;21:1096–103. doi:10.1038/mt.2013.32. PMID:23609015.
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Nemunaitis J, Leung PK, Nunan R, Adams J, Chang EH. Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther : the journal of the American Society of Gene Therapy. 2016;24:1697–706. doi:10.1038/mt.2016.135. PMID:27357628.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Tanaka N, Eishi Y, Amagasa T. Transferrin receptor in oral tumors. Int J Oral Maxillofac Surg. 1994;23:430–3. doi:10.1016/S0901-5027(05)80039-6. PMID:7890992.
   PubMed Web of Science ®Google Scholar
• Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, ET AL. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014;20:2873–84. doi:10.1158/1078-0432.CCR-14-0205. PMID:24668645.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008. PMID:23157435.
   PubMed Web of Science ®Google Scholar
• Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35:88–93. doi:10.1016/j.it.2013.10.010. PMID:24309426.
   PubMed Web of Science ®Google Scholar
• Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, ET AL. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830–42. doi:10.1016/j.immuni.2014.10.017. PMID:25517615.
   PubMed Web of Science ®Google Scholar
• Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol. 2016;6:7. doi:10.3389/fonc.2016.00007. PMID:26858935.
   PubMed Web of Science ®Google Scholar
• Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, ET AL. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015;112:15408–13. doi:10.1073/pnas.1512832112. PMID:26607445.
   PubMed Web of Science ®Google Scholar
• Moore E, Clavijo PE, Davis R, Cash H, Van Waes C, Kim Y, Allen C. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res. 2016;4(12):1061–71. doi:10.1158/2326-6066.CIR-16-0104.
   Web of Science ®Google Scholar
• Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-Sastre A, Lee SW, Aaronson SA. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med. 2008;205:1929–38. doi:10.1084/jem.20080383. PMID:18663127.
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008. doi:10.1101/cshperspect.a001008. PMID:20182602.
   PubMed Web of Science ®Google Scholar
• Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene. 2004;23:2347–56. doi:10.1038/sj.onc.1207405. PMID:14743208.
   PubMed Web of Science ®Google Scholar
• Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash H, Chen Z, Silvin C, Van Waes C, Allen C. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kdelta/gamma. Cancer Res. 2017;77:2607–19. doi:10.1158/0008-5472.CAN-16-2534. PMID:28364000.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, ET AL. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65. doi:10.1016/S1470-2045(16)30066-3. PMID:27247226.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, ET AL. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67. doi:10.1056/NEJMoa1602252. PMID:27718784.
   PubMed Web of Science ®Google Scholar
• Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C, Allen C. mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget. 2015;6:36400–17. PMID:26506415.
   PubMed Web of Science ®Google Scholar
• Morisada M, Moore EC, Hodge R, Friedman J, Cash HA, Hodge JW, Mitchell JB, Allen CT. Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncol. 2017;71:87–94. doi:10.1016/j.oraloncology.2017.06.005. PMID:28688697.
   PubMed Web of Science ®Google Scholar
• Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunol Res. 2016;4:611–20. doi:10.1158/2326-6066.CIR-15-0252. PMID:27076449.
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther. 2006;17:117–24. doi:10.1089/hum.2006.17.117. PMID:16409130.
   PubMed Web of Science ®Google Scholar